Brodimoprim, a New Bacterial Dihydrofolate Reductase Inhibitor: a Minireview
- 1 January 1995
- journal article
- review article
- Published by Informa UK Limited in Journal of Chemotherapy
- Vol. 7 (3), 221-223
- https://doi.org/10.1179/joc.1995.7.3.221
Abstract
This brief review article synthesizes the principal literature regarding the clinical status of co-trimoxazole compared to monotherapy with one of the two diaminopyrimidines available commercially: trimethoprim or brodimoprim. Both these inhibitors of bacterial dihydrofolate reductase compare favorably to co-trimoxazole as antimicrobial chemotherapy. Brodimoprim is characterized by its advantageous pharmacokinetics in comparison to both co-trimoxazole and trimethoprim.Keywords
This publication has 5 references indexed in Scilit:
- Trends in Gram-Positive Bloodstream Organism Resistance: a Seven-Year Audit of Five Glycopeptides and Other Drugs at a Large University HospitalJournal of Chemotherapy, 1993
- Trimethoprim resistance; epidemiology and molecular aspects: --a review based upon a Symposium held on 19 April 1989 at the 4th European Congress of Clinical Microbiology, Nice, FranceJournal of Medical Microbiology, 1990
- Properties of Brodimoprim as an Inhibitor of Dihydrofolate ReductasesChemotherapy, 1984
- Co-trimoxazole or Trimethoprim Alone?Drugs, 1982
- Trimethoprim-SulphamethoxazoleDrugs, 1971